Search Results - "PARHAM, Laura R"

  • Showing 1 - 5 results of 5
Refine Results
  1. 1

    Prospective Validation of HLA-DRB107:01 Allele Carriage As a Predictive Risk Factor for Lapatinib-Induced Liver Injury by SCHAID, Daniel J, SPRAGGS, Colin F, GOSS, Paul E, MCDONNELL, Shannon K, PARHAM, Laura R, COX, Charles J, EJLERTSEN, Bent, FINKELSTEIN, Dianne M, RAPPOLD, Erica, CURRAN, Joan, CARDON, Lon R

    Published in Journal of clinical oncology (01-08-2014)
    “…Liver injury is a serious adverse event leading to permanent discontinuation of lapatinib in affected patients. This study aimed to validate previously…”
    Get full text
    Journal Article
  2. 2

    Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis by Condreay, Lynn D., Parham, Laura R., Qu, Xiaoyan A., Steinfeld, Jonathan, Wechsler, Michael E., Raby, Benjamin A., Yancey, Steven W., Ghosh, Soumitra

    Published in Rheumatology international (01-08-2020)
    “…Treatment of patients with the rare disease eosinophilic granulomatosis with polyangiitis (EGPA) with mepolizumab, a monoclonal antibody to interleukin-5…”
    Get full text
    Journal Article
  3. 3

    Rash in lapatinib-treated patients is not associated with human leukocyte antigen polymorphisms by Parham, Laura R, Briley, Linda P, King, Karen S, Byrne, Julie, Rappold, Erica, Goss, Paul E, Spraggs, Colin F

    Published in Pharmacogenomics (01-07-2015)
    “…Rash is a common side effect of lapatinib treatment. Since human leukocyte antigen ( ) alleles have been implicated in multiple drug-induced cutaneous…”
    Get full text
    Journal Article
  4. 4
  5. 5

    VEGF polymorphism may be associated with overall survival in lapatinib-treated breast cancer patients with brain metastases by Spraggs, Colin F., Li, Li, Briley, Linda P., Joshi, Alaknanda, Florance, Allison M., King, Karen, Parham, Laura R

    Published in Journal of clinical oncology (20-05-2012)
    “…Abstract only 10532 Background: Lapatinib is a dual HER2/EGFR tyrosine kinase inhibitor (TKI) approved in combination with capecitabine or letrozole for…”
    Get full text
    Journal Article